




The relative strengths and weaknesses of Agios Pharmaceuticals INC are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Agios Pharmaceuticals INC compared to the market average is the variable Stockholders Equity, increasing the Economic Capital Ratio by 117% points. The greatest weakness of Agios Pharmaceuticals INC is the variable Research and Development, reducing the Economic Capital Ratio by 10% points.

The company's Economic Capital Ratio, given in the ranking table, is 347%, being 104% points above the market average of 243%.

Input Variable	Value in 1000 USD
Assets, Current	169,747
Cost of Goods Sold	0
Intangible Assets	0
Liabilities, Current	36,930
Liabilities, Non-Current	0
Other Assets	27,700
Other Compr. Net Income	16
Other Expenses	579
Other Liabilities	0
Other Net Income	55
Other Revenues	25,548
Property and Equipment	3,758
Research and Development	54,502
Selling, General and Administrative Expense	9,929

Output Variable	Value in 1000 USD
Assets	201,205
Liabilities	36,930
Expenses	65,010
Revenues	25,548
Stockholders Equity	164,275
Net Income	-39,407
Comprehensive Net Income	-39,399
BaseVar	164,382
ECR before LimitedLiability	268%
Economic Capital Ratio	347%